Committee Composition

  Audit Compensation Nominating and Governance
Kent Kresa Chairman of the Board   Committee Chair for Compensation Committee Member of Nominating and Governance Committee
Ronald Consiglio Independent Director Committee Chair for Audit Committee   Member of Nominating and Governance Committee
Michael Friedman, M.D. Independent Director   Member of Compensation Committee Committee Chair for Nominating and Governance Committee
David H. MacCallum Independent Director Member of Audit Committee    
Henry L. Nordhoff Independent Director Member of Audit Committee    
James S. Shannon Independent Director   Member of Compensation Committee  
Director

James S. Shannon, M.D., MRCP (UK) rejoined our board in May 2015 after previously serving as a director from February 2010 until April 2012. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the position of Global Head of Pharma Development at Novartis AG, based in Basel, Switzerland from 2005 until 2008. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon led of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba-Geigy Ltd and Sandoz. Following the merger he was appointed Head of the Cardiovascular Strategic Team and subsequently became Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. Between 2008 and joining GSK, Dr. Shannon served on the boards of a number of companies, including Biotie, Circassia, Crucell, Endocyte and MannKind. He also sat on the board of Cerimon Pharmaceuticals where he held the position of interim Chief Executive Officer and President from January 2009 until April 2010. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop Inc., working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of research and development ultimately serving as Senior Vice-President, Clinical Development. Dr. Shannon is trained in Medicine and Cardiology. He received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK).


Holdings: 12,738 shares     View Transactions
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director   = Financial Expert

Stock transaction information provided by EDGAR Online. MannKind Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.

MNKD

Exchange:
NASDAQ GM and TASE(US Dollar)

Price: 1.61

Change: 0.08 (5.229%)

Volume: 2,158,304

Data as of
06/23/2017 11:22 AM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More